Efficacy and Safety of Lonapegsomatropin in Children With Turner Syndrome: 52-Week Results From the New InsiGHTS Trial

Clicks: 11
ID: 334175
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #428 of 448 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 448 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CONTEXT: Treatment with growth hormone is effective in improving height outcomes in children with Turner syndrome. However, poor adherence-often influenced by daily injection burden-may compromise treatment outcomes. Lonapegsomatropin is a prodrug, administered once weekly, that provides sustained release of somatropin. OBJECTIVE: To evaluate the efficacy and safety of lonapegsomatropin in children with Turner syndrome. DESIGN: New InsiGHTS is a phase 2 dose-ranging trial (ClinicalTrials.gov: NCT05690386). SETTING: This trial was conducted across 19 centers in the United States. PARTICIPANTS: This trial enrolled and dosed 49 prepubertal children with Turner syndrome. INTERVENTIONS: Randomization was 1:1:1:1 to receive once-weekly lonapegsomatropin (0.24, 0.30, or 0.36 mg hGH/kg/week) or daily somatropin (0.35 mg/kg/week). MAIN OUTCOME MEASURE: The primary efficacy endpoint was annualized height velocity (AHV) at week 26. Secondary efficacy endpoints included AHV at week 52 and change from baseline in height standard deviation score (SDS) at weeks 26 and 52. RESULTS: At week 26, AHV was comparable between lonapegsomatropin starting dose cohorts (range: 9.23 to 10.36 cm/year) and the somatropin cohort (10.86 cm/year). At week 52, AHV was comparable between pooled lonapegsomatropin cohorts (9.05 cm/year) and the somatropin cohort (9.04 cm/year), with mean gains in height SDS of 0.60 and 0.67, respectively. Lonapegsomatropin was well tolerated with a safety profile similar to somatropin. CONCLUSIONS: Across evaluated doses, lonapegsomatropin treatment demonstrated comparable efficacy, safety, and tolerability to somatropin after 1 year, supporting development of lonapegsomatropin as a once-weekly treatment option for short stature in children with Turner syndrome.
Reference Key
openalex_W7223701644 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shanlee Davis, Mary Jennifer Abuzzahab, Jeanie B. Tryggestad, Patricia Y. Fechner, Iris Gutmark‐Little, Katie Woods, Doris Fadoju, Diane E. J. Stafford, Benjamin Udoka Nwosu, Jennifer M. Iklé, Sohair Abdelrahman, Xiaoa Zhen, Meng Mao, Allison Komirenko, Aimee D Shu, Karen Oerter Klein, New InsiGHTS Investigator Group, Mauri Carakushansky, Asheesh Kumar Dewan, Hector Granados, Reema Habiby, Jennifer Law, Lynne Levistsky, Joshua Smith, Paul S. Thornton, Supamit Ukarapong
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag436
URL
https://doi.org/10.1210/clinem/dgag436
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.